These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1528 related articles for article (PubMed ID: 26510911)

  • 1. Arsenic trioxide disrupts glioma stem cells via promoting PML degradation to inhibit tumor growth.
    Zhou W; Cheng L; Shi Y; Ke SQ; Huang Z; Fang X; Chu CW; Xie Q; Bian XW; Rich JN; Bao S
    Oncotarget; 2015 Nov; 6(35):37300-15. PubMed ID: 26510911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methylated arsenic metabolites bind to PML protein but do not induce cellular differentiation and PML-RARα protein degradation.
    Wang QQ; Zhou XY; Zhang YF; Bu N; Zhou J; Cao FL; Naranmandura H
    Oncotarget; 2015 Sep; 6(28):25646-59. PubMed ID: 26213848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Arsenic trioxide and promyelocytic leukemia protein-adenovirus synergistically inhibit in vitro and in vivo growth of a hepatoma cell line.
    Cui L; Zhang S; Zhang W; Hu Z; Cao Z; Li T
    Oncol Res; 2010; 18(7):305-14. PubMed ID: 20377131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Arsenic trioxide sensitizes glioblastoma to a myc inhibitor.
    Yoshimura Y; Shiino A; Muraki K; Fukami T; Yamada S; Satow T; Fukuda M; Saiki M; Hojo M; Miyamoto S; Onishi N; Saya H; Inubushi T; Nozaki K; Tanigaki K
    PLoS One; 2015; 10(6):e0128288. PubMed ID: 26038891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Importance of ERK activation in As2O3-induced differentiation and promyelocytic leukemia nuclear bodies formation in neuroblastoma cells.
    Petit A; Delaune A; Falluel-Morel A; Goullé JP; Vannier JP; Dubus I; Vasse M
    Pharmacol Res; 2013 Nov; 77():11-21. PubMed ID: 24004656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PML mediates glioblastoma resistance to mammalian target of rapamycin (mTOR)-targeted therapies.
    Iwanami A; Gini B; Zanca C; Matsutani T; Assuncao A; Nael A; Dang J; Yang H; Zhu S; Kohyama J; Kitabayashi I; Cavenee WK; Cloughesy TF; Furnari FB; Nakamura M; Toyama Y; Okano H; Mischel PS
    Proc Natl Acad Sci U S A; 2013 Mar; 110(11):4339-44. PubMed ID: 23440206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
    Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
    Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. miR128-1 inhibits the growth of glioblastoma multiforme and glioma stem-like cells via targeting BMI1 and E2F3.
    Shan ZN; Tian R; Zhang M; Gui ZH; Wu J; Ding M; Zhou XF; He J
    Oncotarget; 2016 Nov; 7(48):78813-78826. PubMed ID: 27705931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML.
    Zhang XW; Yan XJ; Zhou ZR; Yang FF; Wu ZY; Sun HB; Liang WX; Song AX; Lallemand-Breitenbach V; Jeanne M; Zhang QY; Yang HY; Huang QH; Zhou GB; Tong JH; Zhang Y; Wu JH; Hu HY; de Thé H; Chen SJ; Chen Z
    Science; 2010 Apr; 328(5975):240-3. PubMed ID: 20378816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARalpha independent manner.
    Wang ZG; Rivi R; Delva L; König A; Scheinberg DA; Gambacorti-Passerini C; Gabrilove JL; Warrell RP; Pandolfi PP
    Blood; 1998 Sep; 92(5):1497-504. PubMed ID: 9716575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor alpha degradation.
    Lallemand-Breitenbach V; Zhu J; Puvion F; Koken M; Honoré N; Doubeikovsky A; Duprez E; Pandolfi PP; Puvion E; Freemont P; de Thé H
    J Exp Med; 2001 Jun; 193(12):1361-71. PubMed ID: 11413191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-neoplastic activity of low-dose endothelial-monocyte activating polypeptide-II results from defective autophagy and G2/M arrest mediated by PI3K/Akt/FoxO1 axis in human glioblastoma stem cells.
    Liu J; Liu L; Xue Y; Meng F; Li S; Wang P; Liu Y
    Biochem Pharmacol; 2014 Jun; 89(4):477-89. PubMed ID: 24792437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of SUMO in RNF4-mediated promyelocytic leukemia protein (PML) degradation: sumoylation of PML and phospho-switch control of its SUMO binding domain dissected in living cells.
    Percherancier Y; Germain-Desprez D; Galisson F; Mascle XH; Dianoux L; Estephan P; Chelbi-Alix MK; Aubry M
    J Biol Chem; 2009 Jun; 284(24):16595-16608. PubMed ID: 19380586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel drug conjugate, NEO212, targeting proneural and mesenchymal subtypes of patient-derived glioma cancer stem cells.
    Jhaveri N; Agasse F; Armstrong D; Peng L; Commins D; Wang W; Rosenstein-Sisson R; Vaikari VP; Santiago SV; Santos T; Chen L; Schönthal AH; Chen TC; Hofman FM
    Cancer Lett; 2016 Feb; 371(2):240-50. PubMed ID: 26683773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tetraspanin CD9 stabilizes gp130 by preventing its ubiquitin-dependent lysosomal degradation to promote STAT3 activation in glioma stem cells.
    Shi Y; Zhou W; Cheng L; Chen C; Huang Z; Fang X; Wu Q; He Z; Xu S; Lathia JD; Ping Y; Rich JN; Bian XW; Bao S
    Cell Death Differ; 2017 Jan; 24(1):167-180. PubMed ID: 27740621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The helicase HAGE prevents interferon-α-induced PML expression in ABCB5+ malignant melanoma-initiating cells by promoting the expression of SOCS1.
    Mathieu MG; Miles AK; Ahmad M; Buczek ME; Pockley AG; Rees RC; Regad T
    Cell Death Dis; 2014 Feb; 5(2):e1061. PubMed ID: 24525737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effects of arsenic trioxide on the subcellular localization of PML/PML-RARalpha protein in leukemic cells].
    Ni J; Chen G; Zhu J; Zhong H; Tang W; Li X; Xiong S; Shen Z; Chen S; Wang Z; Chen L
    Zhonghua Xue Ye Xue Za Zhi; 1997 Jan; 18(1):32-4. PubMed ID: 15622748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations.
    Zhu XH; Shen YL; Jing YK; Cai X; Jia PM; Huang Y; Tang W; Shi GY; Sun YP; Dai J; Wang ZY; Chen SJ; Zhang TD; Waxman S; Chen Z; Chen GQ
    J Natl Cancer Inst; 1999 May; 91(9):772-8. PubMed ID: 10328107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metformin and temozolomide act synergistically to inhibit growth of glioma cells and glioma stem cells in vitro and in vivo.
    Yu Z; Zhao G; Xie G; Zhao L; Chen Y; Yu H; Zhang Z; Li C; Li Y
    Oncotarget; 2015 Oct; 6(32):32930-43. PubMed ID: 26431379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new 2-pyrone derivative, 5-bromo-3-(3-hydroxyprop-1-ynyl)-2H-pyran-2-one, suppresses stemness in glioma stem-like cells.
    Kim RK; Kim MJ; Yoon CH; Lim EJ; Yoo KC; Lee GH; Kim YH; Kim H; Jin YB; Lee YJ; Cho CG; Oh YS; Gye MC; Suh Y; Lee SJ
    Mol Pharmacol; 2012 Sep; 82(3):400-7. PubMed ID: 22648970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 77.